South Carolina Medicaid spending on GLP-1 drugs

How much did South Carolina Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $64.9 million for GLP-1 drugs paid through South Carolina Medicaid in 2025, across at least 65,093 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 105 rows of 279, so these figures are floors.

Pharmacies were reimbursed at least $15.8 million for GLP-1 drugs paid through South Carolina Medicaid in 2026 (quarter 1 only, as posted so far), across at least 16,018 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 31 rows of 71, so these figures are floors.

By year and ingredient

2020at least $4,720,872No dataat least $5,069,001at least $4,367,971at least $1,196,001$70,941at least $17,161at least $15,441,946
2021at least $8,199,086No dataat least $4,461,952at least $6,874,237at least $1,007,023at least $31,969Suppressedat least $20,574,267
2022at least $15,739,609at least $113,725at least $2,937,185at least $11,968,418at least $1,035,946at least $44,728Suppressedat least $31,839,609
2023at least $26,626,502at least $4,010,147at least $1,279,490at least $16,765,465at least $859,219at least $67,801Suppressedat least $49,608,625
2024at least $33,708,610at least $8,610,703at least $303,013at least $10,621,928at least $434,645at least $17,085Suppressedat least $53,695,983
2025at least $46,851,701at least $9,464,453at least $116,795at least $8,467,971at least $44,604SuppressedSuppressedat least $64,945,523
2026 (Q1)at least $10,273,583at least $3,301,875at least $60,293$2,139,593No dataSuppressedSuppressedat least $15,775,344

By product, 2025

Ozempicat least $33,609,410at least 35,2933 of 26
Rybelsusat least $580,854at least 61611 of 24
Wegovyat least $12,661,437at least 9,9116 of 40
Mounjaroat least $8,048,290at least 8,52911 of 52
Zepboundat least $1,416,163at least 1,44114 of 32
Liraglutide (generic name listing)at least $28,968at least 6632 of 36
SaxendaSuppressedSuppressed3 of 3
Victozaat least $87,826at least 1417 of 14
Trulicityat least $8,467,971at least 9,0391 of 33
Bydureonat least $44,604at least 574 of 6
ByettaSuppressedSuppressed1 of 1
Exenatide (generic name listing)SuppressedSuppressed1 of 1
SoliquaSuppressedSuppressed6 of 6
XultophySuppressedSuppressed5 of 5

By quarter, 2025

Q1 2025at least $14,665,784at least 15,18730 of 68
Q2 2025at least $14,370,533at least 14,30728 of 71
Q3 2025at least $18,299,217at least 18,18224 of 71
Q4 2025at least $17,609,989at least 17,41723 of 69

By quarter, 2026 (posted so far)

Q1 2026at least $15,775,344at least 16,01831 of 71

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.